Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study
•First-line crizotinib treatment is beneficial in Chinese patients with ROS1-positive advanced NSCLC.•Involvement of more than two metastatic organs was an independent factor associated with shorter PFS.•G2032R mutation in the ROS1 kinase domain was the most common mechanism of resistance to crizoti...
Gespeichert in:
| Veröffentlicht in: | Lung cancer (Amsterdam, Netherlands) Netherlands), 2020-09, Vol.147, p.130-136 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 136 |
|---|---|
| container_issue | |
| container_start_page | 130 |
| container_title | Lung cancer (Amsterdam, Netherlands) |
| container_volume | 147 |
| creator | Zheng, Jing Cao, He Li, Yuping Rao, Chuangzhou Zhang, Te Luo, Jiayou Lv, Dongqing Zhu, Yanping Zhou, Jianya Zhou, Jianying |
| description | •First-line crizotinib treatment is beneficial in Chinese patients with ROS1-positive advanced NSCLC.•Involvement of more than two metastatic organs was an independent factor associated with shorter PFS.•G2032R mutation in the ROS1 kinase domain was the most common mechanism of resistance to crizotinib.
ROS1 rearrangements are seen in 1–2 % of non-small cell lung cancer (NSCLC) patients. The aim of this study was to determine the effectiveness of crizotinib as first-line treatment in patients with ROS1 rearranged NSCLC.
The data of 56 patients with ROS1-rearranged advanced NSCLC who received first-line crizotinib treatment from 5 hospitals in China were retrospectively reviewed. The clinical characteristics, outcomes of first-line crizotinib therapy and prognostic factors were evaluated. In addition, mechanisms of resistance to crizotinib were analyzed in a cohort of crizotinib-resistant patients.
The median age of the cohort was 53.0 years and most patients (91.1 %) had adenocarcinomas. The median progression free survival (mPFS) after first-line crizotinib therapy was 23.0 months, and the median overall survival (mOS) was 60.0 months. In the univariate analysis, mPFS was significantly shorter in female patients compared to males (12.0 months versus 24.0 months; p = 0.015) and in patients with >2 baseline metastatic organ involvement compared to those with ≤2 baseline metastatic organ involvement (4.0 months vs 24.0 months; p < 0.001).In addition, the mOS was significantly shorter in patients with >2 baseline metastatic organ involvement relative to that in patients with ≤2 baseline metastatic organ involvement (6.0 months vs 60.0 months; p < 0.001). Multivariable analysis further showed that >2 baseline metastatic organ involvement was the only independent prognostic factor of PFS (p = 0.008). Four out of 8 patients (50 %) with crizotinib resistance harbored a G2032R mutation in the ROS1 kinase domain.
First-line crizotinib treatment is beneficial in Chinese patients with ROS1-rearranged advanced NSCLC. Resistance to crizotinib correlated with the G2032R mutation in the ROS1 kinase domain. |
| doi_str_mv | 10.1016/j.lungcan.2020.07.016 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2427305488</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169500220305389</els_id><sourcerecordid>2427305488</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-6b1e692de8992e426b1d961ed82e2a8bec772ca7ac3728a40845d2a616666aac3</originalsourceid><addsrcrecordid>eNqFUcuOFCEUJUbjtKOfoLlLN1UC9YByYyaT8ZFMMomPNaHhVkunimqBGjN-kN_p7XTrVhY8DudwD_cw9lLwWnDRv9nX0xp3zsZacslrrmpCH7GN0EpWumnkY7YhZKg6zuUFe5bznnOhBB-esotGKi67ftiw3zfjiK6Ee4yYM9jo4ZCWXVxyCQ5G68qSMiwjjCHlUk0hIrgUfi0lxLCFktCWGWOBEOFgS6Bthp-hfIfPd19ERdcp2bhDD3GJVZ7tNIFDmo7ugew7TG_hCuZ1ooKkxgQJS1ry4WQLcln9w3P2ZLRTxhfn9ZJ9e3_z9fpjdXv34dP11W3lmr4rVb8V2A_Sox4Gia2ksx96gV5LlFZv0SklnVXWNUpq23Lddl7aXvQ0LKGX7PXpXWrCjxVzMXPIR7824rJmI1upGt61WhO1O1Edmc0JR3NIYbbpwQhujhGZvTlHZI4RGa4MoaR7dS6xbmf0_1R_MyHCuxMB6aP3AZPJjvrq0IdEPTF-Cf8p8QdLVqlw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2427305488</pqid></control><display><type>article</type><title>Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Zheng, Jing ; Cao, He ; Li, Yuping ; Rao, Chuangzhou ; Zhang, Te ; Luo, Jiayou ; Lv, Dongqing ; Zhu, Yanping ; Zhou, Jianya ; Zhou, Jianying</creator><creatorcontrib>Zheng, Jing ; Cao, He ; Li, Yuping ; Rao, Chuangzhou ; Zhang, Te ; Luo, Jiayou ; Lv, Dongqing ; Zhu, Yanping ; Zhou, Jianya ; Zhou, Jianying</creatorcontrib><description>•First-line crizotinib treatment is beneficial in Chinese patients with ROS1-positive advanced NSCLC.•Involvement of more than two metastatic organs was an independent factor associated with shorter PFS.•G2032R mutation in the ROS1 kinase domain was the most common mechanism of resistance to crizotinib.
ROS1 rearrangements are seen in 1–2 % of non-small cell lung cancer (NSCLC) patients. The aim of this study was to determine the effectiveness of crizotinib as first-line treatment in patients with ROS1 rearranged NSCLC.
The data of 56 patients with ROS1-rearranged advanced NSCLC who received first-line crizotinib treatment from 5 hospitals in China were retrospectively reviewed. The clinical characteristics, outcomes of first-line crizotinib therapy and prognostic factors were evaluated. In addition, mechanisms of resistance to crizotinib were analyzed in a cohort of crizotinib-resistant patients.
The median age of the cohort was 53.0 years and most patients (91.1 %) had adenocarcinomas. The median progression free survival (mPFS) after first-line crizotinib therapy was 23.0 months, and the median overall survival (mOS) was 60.0 months. In the univariate analysis, mPFS was significantly shorter in female patients compared to males (12.0 months versus 24.0 months; p = 0.015) and in patients with >2 baseline metastatic organ involvement compared to those with ≤2 baseline metastatic organ involvement (4.0 months vs 24.0 months; p < 0.001).In addition, the mOS was significantly shorter in patients with >2 baseline metastatic organ involvement relative to that in patients with ≤2 baseline metastatic organ involvement (6.0 months vs 60.0 months; p < 0.001). Multivariable analysis further showed that >2 baseline metastatic organ involvement was the only independent prognostic factor of PFS (p = 0.008). Four out of 8 patients (50 %) with crizotinib resistance harbored a G2032R mutation in the ROS1 kinase domain.
First-line crizotinib treatment is beneficial in Chinese patients with ROS1-rearranged advanced NSCLC. Resistance to crizotinib correlated with the G2032R mutation in the ROS1 kinase domain.</description><identifier>ISSN: 0169-5002</identifier><identifier>EISSN: 1872-8332</identifier><identifier>DOI: 10.1016/j.lungcan.2020.07.016</identifier><identifier>PMID: 32702569</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; China ; Crizotinib ; Crizotinib - therapeutic use ; Effectiveness ; Female ; First-line treatment ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Male ; Middle Aged ; Non-small cell lung cancer ; Prognosis ; Prognostic factors ; Protein Kinase Inhibitors - therapeutic use ; Protein-Tyrosine Kinases - genetics ; Proto-Oncogene Proteins - genetics ; Resistance mechanisms ; Retrospective Studies</subject><ispartof>Lung cancer (Amsterdam, Netherlands), 2020-09, Vol.147, p.130-136</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-6b1e692de8992e426b1d961ed82e2a8bec772ca7ac3728a40845d2a616666aac3</citedby><cites>FETCH-LOGICAL-c365t-6b1e692de8992e426b1d961ed82e2a8bec772ca7ac3728a40845d2a616666aac3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.lungcan.2020.07.016$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3541,27915,27916,45986</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32702569$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zheng, Jing</creatorcontrib><creatorcontrib>Cao, He</creatorcontrib><creatorcontrib>Li, Yuping</creatorcontrib><creatorcontrib>Rao, Chuangzhou</creatorcontrib><creatorcontrib>Zhang, Te</creatorcontrib><creatorcontrib>Luo, Jiayou</creatorcontrib><creatorcontrib>Lv, Dongqing</creatorcontrib><creatorcontrib>Zhu, Yanping</creatorcontrib><creatorcontrib>Zhou, Jianya</creatorcontrib><creatorcontrib>Zhou, Jianying</creatorcontrib><title>Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study</title><title>Lung cancer (Amsterdam, Netherlands)</title><addtitle>Lung Cancer</addtitle><description>•First-line crizotinib treatment is beneficial in Chinese patients with ROS1-positive advanced NSCLC.•Involvement of more than two metastatic organs was an independent factor associated with shorter PFS.•G2032R mutation in the ROS1 kinase domain was the most common mechanism of resistance to crizotinib.
ROS1 rearrangements are seen in 1–2 % of non-small cell lung cancer (NSCLC) patients. The aim of this study was to determine the effectiveness of crizotinib as first-line treatment in patients with ROS1 rearranged NSCLC.
The data of 56 patients with ROS1-rearranged advanced NSCLC who received first-line crizotinib treatment from 5 hospitals in China were retrospectively reviewed. The clinical characteristics, outcomes of first-line crizotinib therapy and prognostic factors were evaluated. In addition, mechanisms of resistance to crizotinib were analyzed in a cohort of crizotinib-resistant patients.
The median age of the cohort was 53.0 years and most patients (91.1 %) had adenocarcinomas. The median progression free survival (mPFS) after first-line crizotinib therapy was 23.0 months, and the median overall survival (mOS) was 60.0 months. In the univariate analysis, mPFS was significantly shorter in female patients compared to males (12.0 months versus 24.0 months; p = 0.015) and in patients with >2 baseline metastatic organ involvement compared to those with ≤2 baseline metastatic organ involvement (4.0 months vs 24.0 months; p < 0.001).In addition, the mOS was significantly shorter in patients with >2 baseline metastatic organ involvement relative to that in patients with ≤2 baseline metastatic organ involvement (6.0 months vs 60.0 months; p < 0.001). Multivariable analysis further showed that >2 baseline metastatic organ involvement was the only independent prognostic factor of PFS (p = 0.008). Four out of 8 patients (50 %) with crizotinib resistance harbored a G2032R mutation in the ROS1 kinase domain.
First-line crizotinib treatment is beneficial in Chinese patients with ROS1-rearranged advanced NSCLC. Resistance to crizotinib correlated with the G2032R mutation in the ROS1 kinase domain.</description><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>China</subject><subject>Crizotinib</subject><subject>Crizotinib - therapeutic use</subject><subject>Effectiveness</subject><subject>Female</subject><subject>First-line treatment</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Non-small cell lung cancer</subject><subject>Prognosis</subject><subject>Prognostic factors</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Protein-Tyrosine Kinases - genetics</subject><subject>Proto-Oncogene Proteins - genetics</subject><subject>Resistance mechanisms</subject><subject>Retrospective Studies</subject><issn>0169-5002</issn><issn>1872-8332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUcuOFCEUJUbjtKOfoLlLN1UC9YByYyaT8ZFMMomPNaHhVkunimqBGjN-kN_p7XTrVhY8DudwD_cw9lLwWnDRv9nX0xp3zsZacslrrmpCH7GN0EpWumnkY7YhZKg6zuUFe5bznnOhBB-esotGKi67ftiw3zfjiK6Ee4yYM9jo4ZCWXVxyCQ5G68qSMiwjjCHlUk0hIrgUfi0lxLCFktCWGWOBEOFgS6Bthp-hfIfPd19ERdcp2bhDD3GJVZ7tNIFDmo7ugew7TG_hCuZ1ooKkxgQJS1ry4WQLcln9w3P2ZLRTxhfn9ZJ9e3_z9fpjdXv34dP11W3lmr4rVb8V2A_Sox4Gia2ksx96gV5LlFZv0SklnVXWNUpq23Lddl7aXvQ0LKGX7PXpXWrCjxVzMXPIR7824rJmI1upGt61WhO1O1Edmc0JR3NIYbbpwQhujhGZvTlHZI4RGa4MoaR7dS6xbmf0_1R_MyHCuxMB6aP3AZPJjvrq0IdEPTF-Cf8p8QdLVqlw</recordid><startdate>202009</startdate><enddate>202009</enddate><creator>Zheng, Jing</creator><creator>Cao, He</creator><creator>Li, Yuping</creator><creator>Rao, Chuangzhou</creator><creator>Zhang, Te</creator><creator>Luo, Jiayou</creator><creator>Lv, Dongqing</creator><creator>Zhu, Yanping</creator><creator>Zhou, Jianya</creator><creator>Zhou, Jianying</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202009</creationdate><title>Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study</title><author>Zheng, Jing ; Cao, He ; Li, Yuping ; Rao, Chuangzhou ; Zhang, Te ; Luo, Jiayou ; Lv, Dongqing ; Zhu, Yanping ; Zhou, Jianya ; Zhou, Jianying</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-6b1e692de8992e426b1d961ed82e2a8bec772ca7ac3728a40845d2a616666aac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>China</topic><topic>Crizotinib</topic><topic>Crizotinib - therapeutic use</topic><topic>Effectiveness</topic><topic>Female</topic><topic>First-line treatment</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Non-small cell lung cancer</topic><topic>Prognosis</topic><topic>Prognostic factors</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Protein-Tyrosine Kinases - genetics</topic><topic>Proto-Oncogene Proteins - genetics</topic><topic>Resistance mechanisms</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zheng, Jing</creatorcontrib><creatorcontrib>Cao, He</creatorcontrib><creatorcontrib>Li, Yuping</creatorcontrib><creatorcontrib>Rao, Chuangzhou</creatorcontrib><creatorcontrib>Zhang, Te</creatorcontrib><creatorcontrib>Luo, Jiayou</creatorcontrib><creatorcontrib>Lv, Dongqing</creatorcontrib><creatorcontrib>Zhu, Yanping</creatorcontrib><creatorcontrib>Zhou, Jianya</creatorcontrib><creatorcontrib>Zhou, Jianying</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zheng, Jing</au><au>Cao, He</au><au>Li, Yuping</au><au>Rao, Chuangzhou</au><au>Zhang, Te</au><au>Luo, Jiayou</au><au>Lv, Dongqing</au><au>Zhu, Yanping</au><au>Zhou, Jianya</au><au>Zhou, Jianying</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study</atitle><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle><addtitle>Lung Cancer</addtitle><date>2020-09</date><risdate>2020</risdate><volume>147</volume><spage>130</spage><epage>136</epage><pages>130-136</pages><issn>0169-5002</issn><eissn>1872-8332</eissn><abstract>•First-line crizotinib treatment is beneficial in Chinese patients with ROS1-positive advanced NSCLC.•Involvement of more than two metastatic organs was an independent factor associated with shorter PFS.•G2032R mutation in the ROS1 kinase domain was the most common mechanism of resistance to crizotinib.
ROS1 rearrangements are seen in 1–2 % of non-small cell lung cancer (NSCLC) patients. The aim of this study was to determine the effectiveness of crizotinib as first-line treatment in patients with ROS1 rearranged NSCLC.
The data of 56 patients with ROS1-rearranged advanced NSCLC who received first-line crizotinib treatment from 5 hospitals in China were retrospectively reviewed. The clinical characteristics, outcomes of first-line crizotinib therapy and prognostic factors were evaluated. In addition, mechanisms of resistance to crizotinib were analyzed in a cohort of crizotinib-resistant patients.
The median age of the cohort was 53.0 years and most patients (91.1 %) had adenocarcinomas. The median progression free survival (mPFS) after first-line crizotinib therapy was 23.0 months, and the median overall survival (mOS) was 60.0 months. In the univariate analysis, mPFS was significantly shorter in female patients compared to males (12.0 months versus 24.0 months; p = 0.015) and in patients with >2 baseline metastatic organ involvement compared to those with ≤2 baseline metastatic organ involvement (4.0 months vs 24.0 months; p < 0.001).In addition, the mOS was significantly shorter in patients with >2 baseline metastatic organ involvement relative to that in patients with ≤2 baseline metastatic organ involvement (6.0 months vs 60.0 months; p < 0.001). Multivariable analysis further showed that >2 baseline metastatic organ involvement was the only independent prognostic factor of PFS (p = 0.008). Four out of 8 patients (50 %) with crizotinib resistance harbored a G2032R mutation in the ROS1 kinase domain.
First-line crizotinib treatment is beneficial in Chinese patients with ROS1-rearranged advanced NSCLC. Resistance to crizotinib correlated with the G2032R mutation in the ROS1 kinase domain.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>32702569</pmid><doi>10.1016/j.lungcan.2020.07.016</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0169-5002 |
| ispartof | Lung cancer (Amsterdam, Netherlands), 2020-09, Vol.147, p.130-136 |
| issn | 0169-5002 1872-8332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2427305488 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics China Crizotinib Crizotinib - therapeutic use Effectiveness Female First-line treatment Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Male Middle Aged Non-small cell lung cancer Prognosis Prognostic factors Protein Kinase Inhibitors - therapeutic use Protein-Tyrosine Kinases - genetics Proto-Oncogene Proteins - genetics Resistance mechanisms Retrospective Studies |
| title | Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T05%3A58%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20and%20prognostic%20factors%20of%20first-line%20crizotinib%20treatment%20in%20patients%20with%20ROS1-rearranged%20non-small%20cell%20lung%20cancer:%20A%20multicenter%20retrospective%20study&rft.jtitle=Lung%20cancer%20(Amsterdam,%20Netherlands)&rft.au=Zheng,%20Jing&rft.date=2020-09&rft.volume=147&rft.spage=130&rft.epage=136&rft.pages=130-136&rft.issn=0169-5002&rft.eissn=1872-8332&rft_id=info:doi/10.1016/j.lungcan.2020.07.016&rft_dat=%3Cproquest_cross%3E2427305488%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2427305488&rft_id=info:pmid/32702569&rft_els_id=S0169500220305389&rfr_iscdi=true |